For primary prevention in patients not on statin therapy, we suggest against routinely ordering a lipid panel more frequently than every 10 years. Weak against 3. For cardiovascular risk assessment in primary prevention, we suggest using a 10- year risk calculator. Weak for 4. We suggest against the routine use of coronary artery calcium testing. Weak against 5. We suggest against the routine use of additional risk markers (e.g., high- sensitivity C-reactive protein, ankle-brachial index, coronary artery calcium) when assessing cardiovascular risk. Weak against VA/DoD CPG for the Management of Dyslipidemia for Cardiovascular Risk Reduction Provider Summary Topic Sub- topic # Recommendation Strengtha Pharmacotherapy, Supplements, and Nutraceuticals a. Primary Prevention 6. For primary prevention, we recommend offering a moderate-dose statin in patients with a >12% 10-year cardiovascular risk or low-density lipoprotein cholesterol >190 mg/dL or diabetes. Strong for 7. For primary prevention, we suggest offering a moderate-dose statin for patients with a 10-year cardiovascular risk between 6% and 12% following a discussion of risks, limited benefit, and an exploration of the patient s values and preferences. Weak for 8. For primary prevention in patients on moderate-dose statins, we suggest against maximizing the statin dose due to the lack of evidence proving added cardiovascular benefits and the risks of higher dose statins. Weak against 9. For primary prevention, there is insufficient evidence to recommend for or against using ezetimibe with or without statins. Neither for nor against 10. For primary prevention, we recommend against offering PCSK9 inhibitors due to unknown long-term safety, inconclusive evidence for benefit, and high cost. Strong against b. Secondary Prevention 11. For secondary prevention, we recommend using at least a moderate-dose statin.* Strong for 12. 